ATR inhibition controls aggressive prostate tumors deficient in Y-linked histone demethylase KDM5D
Kazumasa Komura(Kawasaki Medical School), Philip W. Kantoff(Convergent Science (United States)), Naokazu Ibuki, Teppei Shimamura(Systems Biology Institute), Clifford A. Meyer(Dana-Farber Cancer Institute), Joshua Armenia(AstraZeneca (United Kingdom)), Kalyani Chadalavada(Memorial Sloan Kettering Cancer Center), Yuki Yoshikawa(Hiroshima Prefectural Hospital), Haruhito Azuma(Osaka University of Pharmaceutical Sciences), Goutam Chakraborty(National Centre for Cell Science), Gwo‐Shu Mary Lee(Dana-Farber Cancer Institute), Kohei Taniguchi(Osaka University of Pharmaceutical Sciences), Ying Z. Mazzu(Memorial Sloan Kettering Cancer Center), Gouri J. Nanjangud(Memorial Sloan Kettering Cancer Center), Lorelei A. Mucci(American Cancer Society), Travis Gerke(Moffitt Cancer Center), Teruo Inamoto(Hamamatsu University), Kunihiko Hinohara(Broad Institute), Seong Ho Jeong(Inje University Sanggye Paik Hospital), Shin-Yi Du(Memorial Sloan Kettering Cancer Center), Christopher J. Sweeney(The University of Adelaide)
Cited by 79
Related Papers
Model-based Analysis of ChIP-Seq (MACS)
|Genome biology|2008|20k
Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
|New England Journal of Medicine|2010|5.5k
Oncogenic Signaling Pathways in The Cancer Genome Atlas
|Cell|2018|3.4k
Pan-cancer analysis of whole genomes
|Nature|2020|3.3k
The Molecular Taxonomy of Primary Prostate Cancer
|Cell|2015|3.3k